<DOC>
	<DOC>NCT01064453</DOC>
	<brief_summary>Angeliq regulatory Post-Marketing Surveillance (PMS) is to get data about safety and efficacy in real practice for the indication approved by Korea Food and Drug Administration (KFDA). This is non-interventional , prospective, multi-center study.Target number of patients is 4500.</brief_summary>
	<brief_title>Angeliq Regulatory Post Marketing Surveillance</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis, Postmenopausal</mesh_term>
	<mesh_term>Drospirenone and ethinyl estradiol combination</mesh_term>
	<criteria>Hormone replacement therapy for estrogen deficiency symptoms in postmenopausal women more than 1 year postmenopause Prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of osteoporosis Undiagnosed genital bleeding Known, past or suspected cancer of the breast Known or suspected estrogendependent malignant tumors (e.g. endometrial cancer) Untreated endometrial hyperplasia Previous idiopathic or current venous thromboembolism (e.g. deep venous thrombosis, pulmonary embolism) Active or recent arterial thromboembolic disease (e.g. angina, myocardial infarction) Acute liver disease, or a history of liver disease as long as liver function tests have failed to return to normal Porphyria Severe renal insufficiency or acute renal failure Known hypersensitivity to the active substances or to any of the excipients</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Menopause</keyword>
	<keyword>Menopausal symptoms</keyword>
	<keyword>Prevention of osteoporosis in menopausal women</keyword>
	<keyword>Estrogen deficiency symptoms</keyword>
	<keyword>Hormone replacement therapy</keyword>
</DOC>